Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
- Sanofi K.K. Sales Grew 5.7% in 2012, Plavix Enjoys Sales Success
April 11, 2013
- Ethical Drug Sales Fall 1.7% in February as Flu Season Slows Down: Crecon Report
April 11, 2013
- Teva Pharma Voluntarily Recalls Enalapril Maleate Tablets
April 11, 2013
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
- Survey by JCSOA Finds Big Increase in Use of CMRs to Detail Long-Listed and Non-Priority Products
April 8, 2013
- Teijin Acquires 10% Stake in Kyorin for Strategic Alliance
April 8, 2013
- Bell Medical Solutions Concludes Business Alliance Agreement for CRO Business with inVentiv Health Clinical
April 8, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…